News Release

Larysa Baraban receives professorship for Medical Nanotechnology at TUD Dresden University of Technology

Business Announcement

Technische Universität Dresden

Portrait Prof. Larysa Baraban


Prof. Larysa Baraban

view more 

Credit: HZDR / Anja Schneider

Digitalization and technological advances will enable personalized therapies, particularly for the treatment of cancer. Innovative, highly sensitive diagnostics that are seamlessly integrated into devices or clinically relevant instruments are increasingly simplifying patient care. For such applications, Professor Baraban and her team are developing smart, miniaturized biosensors based on nanomaterials and advanced microfluidics. These new technologies can be used to characterize biomolecules and (cancer) cells to fundamentally understand biochemical reactions and processes. Among other things, Baraban has developed a nanochip that can recognize individual cancer characteristics and, based on this information, enable personalized immunotherapy.  

“I am grateful for the trust placed in me and the generous support for my research. The excellent scientific infrastructure in Dresden already enables patient-oriented, interdisciplinary research through the networking of TU Dresden, University Hospital Carl Gustav Carus and research institutions such as the HZDR and the EKFZ for Digital Health. My vision is to contribute to the improvement of precision medicine in clinical oncology with smart materials and bioelectronics. The nano- and microsystems developed for diagnosis, analysis and monitoring make a decisive contribution to better decision-making in diagnostics and therapy planning. The support of the EKFZ for Digital Health and the HZDR enables me to focus my research at the interface between medicine and high-tech even more strongly on clinical needs,” says Prof. Larysa Baraban. 

“We are delighted that Prof. Baraban has accepted the appointment to the Chair of Medical Nanotechnology. She is an outstanding scientist who has already carried out pioneering research in the field of nanotechnology in Dresden, for which she also received an ERC Consolidator Grant. We are pleased that we can further strengthen the long-standing and very successful collaboration between the Faculty of Medicine and the HZDR with this joint professorship. The appointment will give Professor Baraban the necessary support and perspective to further advance her research and develop new technologies for medical diagnostics and treatment,” says Prof. Esther Troost, Dean of the Faculty of Medicine Carl Gustav Carus at TU Dresden. 

With the appointment, Prof. Baraban’s previous position as head of the “Nano-Microsystems for Life Sciences” department at the Institute of Radiopharmaceutical Cancer Research at the HZDR will remain in place. She receives additional funding for her research at the HZDR as part of the Helmholtz first-time professorial appointment program for excellent female scientists.

About the person
Larysa Baraban began her scientific career in Ukraine, where she studied physics at the Taras Shevchenko National University in Kyiv. After successfully completing her studies, she earned her doctorate in experimental physics at the University of Konstanz. In 2009, she joined a French research team at the École Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI) and worked on biotechnologies for the first time. Two years later, she went to the Leibniz Institute for Solid State and Materials Research Dresden (IFW) and then to TU Dresden to specialize in systems in the nanometer range. Since 2020, Baraban has been group leader of the “Nano-microsystems for Life Sciences” research group at the HZDR, which developed into a separate department at the Institute of Radiopharmaceutical Cancer Research at the beginning of 2023. 

Helmholtz-Zentrum Dresden-Rossendorf
The Helmholtz-Zentrum Dresden-Rossendorf (HZDR) performs – as an independent German research center – research in the fields of energy, health, and matter. We focus on answering the following questions:  

  • How can energy and resources be utilized in an efficient, safe, and sustainable way? 
  • How can malignant tumors be more precisely visualized, characterized, and more effectively treated? 
  • How do matter and materials behave under the influence of strong fields and in smallest dimensions? 

To help answer these research questions, HZDR operates large-scale facilities, which are also used by visiting researchers: the Ion Beam Center, the Dresden High Magnetic Field Laboratory and the ELBE Center for High-Power Radiation Sources. HZDR is a member of the Helmholtz Association and has six sites (Dresden, Freiberg, Görlitz, Grenoble, Leipzig, Schenefeld near Hamburg) with almost 1,500 members of staff, of whom about 670 are scientists, including 220 Ph.D. candidates. 

Faculty of Medicine and University Hospital Carl Gustav Carus at TUDDresden University of Technology
Dresden University Medicine, consisting of the Medical Faculty Carl Gustav Carus and the University Hospital of the same name, specializes in research in the fields of oncology, metabolism, neurological and psychiatric diseases. Within these key areas, the topics of degeneration and regeneration, imaging and technology development, immunology and inflammation as well as prevention and care research are of particular interest. Internationality is a prerequisite for cutting-edge research – the University Hospital Carl Gustav Carus Dresden lives this concept with employees from 93 nations and numerous collaborations with researchers and teams from all over the world.

Else Kröner Fresenius Center (EKFZ) for Digital Health
The EKFZ for Digital Health at TU Dresden was established in September 2019. It receives funding of around 40 million euros from the Else Kröner Fresenius Foundation for a period of ten years. The center focuses its research activities on innovative, medical and digital technologies at the direct interface with patients. The aim here is to fully exploit the potential of digitization in medicine to significantly and sustainably improve healthcare, medical research and clinical practice.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.